Equities Analysts Issue Forecasts for CELZ FY2024 Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Equities researchers at Roth Capital upped their FY2024 earnings per share estimates for shares of Creative Medical Technology in a research report issued on Wednesday, November 13th. Roth Capital analyst J. Aschoff now forecasts that the company will earn ($3.19) per share for the year, up from their prior estimate of ($3.29). The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share. Roth Capital also issued estimates for Creative Medical Technology’s Q4 2024 earnings at ($0.63) EPS, FY2025 earnings at ($2.24) EPS, FY2026 earnings at ($2.66) EPS, FY2027 earnings at $3.26 EPS and FY2028 earnings at $6.34 EPS.

Creative Medical Technology Price Performance

NASDAQ CELZ opened at $2.70 on Monday. Creative Medical Technology has a 12 month low of $2.52 and a 12 month high of $10.28. The stock has a market capitalization of $4.72 million, a P/E ratio of -0.71 and a beta of 2.01. The firm’s 50-day moving average is $3.46 and its two-hundred day moving average is $3.69.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently raised its position in Creative Medical Technology stock. Aaron Wealth Advisors LLC increased its position in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) by 19.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,570 shares of the company’s stock after purchasing an additional 3,170 shares during the period. Aaron Wealth Advisors LLC owned 1.45% of Creative Medical Technology worth $75,000 at the end of the most recent quarter. 1.42% of the stock is currently owned by hedge funds and other institutional investors.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.